ASX · CSL.AX
CSL Limited
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
Loading market information…
ASX · RCE.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 05:10 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Recce Pharmaceuticals Ltd’s quoted price sits in the lower half of its reported 52-week range, 50.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Recce Pharmaceuticals Ltd’s next earnings report is currently expected on Mar 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Recce Pharmaceuticals Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| A$0.00-100.0% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$200.73+A$3.23 (+1.64%)
CSL Limited’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
A$2.73+A$0.01 (+0.37%)
Sigma Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 14.69% below the high.
A$196.20-A$0.89 (-0.45%)
Pro Medicus Limited’s quoted price sits in the upper half of its reported 52-week range, 28.09% below the high.
A$55.60+A$0.68 (+1.24%)
Ramsay Health Care Limited’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
A$0.29-A$0.04 (-10.77%)
Island Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 53.97% below the high.
A$0.01-A$0.00 (-16.67%)
Botanix Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 93.33% below the high.
A$0.04A$0.00 (0.0%)
Immuron Limited’s quoted price sits in the lower half of its reported 52-week range, 59.18% below the high.
A$0.00A$0.00 (0.0%)
Biotron Limited’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
